Serenoa repens for benign prostatic hyperplasia
Sübutlu məlumatların xülasələri
17.07.2017 • Sonuncu dəyişiklik 17.07.2017
Editors
Serenoa repens, an herbal medicine, may not improve urinary symptoms and peak urinary flow compared to placebo in men with benign prostatic hyperplasia.
A Cochrane review included 32 studies lasting 4 to 72 weeks with a total of 5 666 subjects. Serenoa repens was not superior in improving International Prostate Symptom Score (IPSS) compared to placebo (MD 0.40 mL/s, 95% CI -0.30 to 1.09).
For nocturia, Serenoa repens was not significantly better than placebo.2 = 66%). A sensitivity analysis, utilizing higher quality, larger trials (≥ 40 subjects), demonstrated no significant difference (WMD -0.31 nocturnal visits, 95% CI -0.70 to 0.08; 5 studies, I2 = 11%). Serenoa repens was not superior to finasteride (MD -0.05 nocturnal visits, 95% CI -0.49 to 0.39; 1 study, n=1097), or to tamsulosin (per cent improvement, RR 0.91, 95% CI 0.66 to 1.27; 1 study, n=542). "?>
Comparing peak urine flow, Serenoa repens was not superior to placebo at trial endpoint (WMD 1.02 mL/s, 95% CI -0.14 to 2.19; 10 studies, n=1019 ), or by comparing mean change (WMD 0.31 mL/s, 95% CI -0.56 to 1.17; 2 studies, n=304 ). Comparing prostate size at endpoint, there was no significant difference between Serenoa repens and placebo (MD -1.05 cc, 95% CI -8.84 to 6.75; 2 studies, n=243), or by comparing mean change (MD -1.22 cc, 95% CI -3.91 to 1.47; 1 study, n=225).
Comparing prostate size (mean change from baseline), one high quality 12-month trial (N = 225) reported no significant difference between SR and placebo (MD -1.22 cc, 95% CI -3.91 to 1.47).
Adverse effects were mild and infrequent.
Comment: The quality of evidence is downgraded by inconsistency (variability in results across studies and heterogeneity in interventions and outcomes), and by imprecise results (wide confidence intervals).
Ədəbiyyat
- Tacklind J, Macdonald R, Rutks I et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012;(12):CD001423.